In fact, previous studies have shown that the Bcr‐Abl oligomerization domain peptide is able to competitively inhibit full‐length Bcr‐Abl oligomerization in a dominant‐negative manner, consequently promoting Ph+ leukemias cell apoptosis, although the efficacy was moderated.[16]. The gene discussed is ABL1; the disease is leukemia.